Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Building any biotech is incredibly hard, so trying to find an 'easy' problem is a fallacy. Instead, founders should choose a massive, impactful problem. The sheer scale of the mission provides the necessary motivation for the team to persist through the inevitable, extreme challenges of development.

Related Insights

Contrary to conventional wisdom, pursuing massive, hard-to-solve ideas makes it easier to attract capital and top talent. Investors prefer the binary risk-reward of huge outcomes, and the best employees want to work on world-changing problems, not incremental improvements like a new calendar app.

The belief required to start a company that solves a massive, complex problem like communication isn't confidence, but a form of delusion. This mindset allows founders to persist through challenges that a more realistic person might abandon, especially when a problem seems fundamentally unsolvable.

Bilyeu stresses the difference between a mission (ending metabolic disease) and a path (making protein bars). A mission is the core 'why' and provides flexibility and resilience. Being married to a specific product path is rigid and risky, as the path may need to change to serve the mission.

Unlike large pharma where novel projects compete with established, safer alternatives, biotech startups derive immense power from their singular focus. The "live or die" mentality on a single hard problem forces teams to innovate and persevere through setbacks, which is essential for pushing true scientific boundaries.

Instead of optimizing for a quick win, founders should be "greedy" and select a problem so compelling they can envision working on it for 10-20 years. This long-term alignment is critical for avoiding the burnout and cynicism that comes from building a business you're not passionate about. The problem itself must be the primary source of motivation.

A full understanding of a complex industry's challenges can be paralyzing. The founder of Buildots admitted he wouldn't have started the company if he knew how hard it would be. Naivety allows founders to tackle enormous problems that experienced operators might avoid entirely.

Founders often fall in love with their solution (e.g., drones for wildfires), but solutions are fragile and constantly change. Adrian Aoun advises entrepreneurs to attach themselves to large, stable problems (e.g., life extension), as the problem's existence is guaranteed, providing a durable foundation for the company.

Solving a big, ambitious problem isn't just for market size; it's a powerful recruiting tool. It's not materially harder than solving a smaller problem, but it attracts more interesting, motivated people who want to work on challenging missions. This talent advantage can be decisive.

The founder of Better Auth argues that all startup ventures are inherently difficult, regardless of their scope. Since the level of effort and hardship will be high either way, founders should choose to work on ambitious, potentially world-changing problems rather than smaller, less impactful ideas.

According to Delphi CEO Susan Tucci, biotech leadership is a unique challenge that requires deliberately choosing difficult but highly rewarding paths. This mindset is crucial for motivating teams through long, arduous development cycles, as the mission's profound impact justifies the struggle.